{"filings":[{"id":500916,"accession_number":"0001193125-26-229076","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2026-05-18T20:51:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Wave Life Sciences WVE-006 phase 1b/2a data shows MZ-like phenotype with monthly dosing, FDA feedback expected mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["WVE-006 achieved 64.4% wild-type M-AAT (matching protective MZ phenotype) and 70.5% reduction in toxic Z-AAT in 200 mg biweekly cohort.","Monthly 400 mg dosing yielded similar results: 58.7% M-AAT, 67.7% Z-AAT reduction, and 13.6 µM total AAT.","Dynamic AAT production restored during acute phase responses (common cold); CRP and AAT strongly correlated (r=0.73, p<0.001).","WVE-006 well tolerated with no serious AEs or liver toxicities; monthly subcutaneous dosing confirmed feasible.","Wave expects FDA feedback on accelerated approval pathway mid-2026; 600 mg monthly cohort data due H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94228,"accession_number":"0001193125-26-183563","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Wave Q1 revenue $38.2M; net loss narrows to $26.1M; WVE-007 Phase 2a begins Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $38.2M (up from $9.2M); net loss $26.1M (vs $46.9M).","Cash $544.6M; runway into Q3 2028, excluding GSK milestones.","FDA accepted Phase 2a multidose portion of WVE-007 (obesity); trial to start Q2 2026.","Phase 1 six-month data: total fat -5.3%, visceral fat -14.3% (p<0.05), muscle +2.4%.","WVE-006 AATD data at ATS May 18 & EASL May 29; accelerated approval feedback mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":38246000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94227,"accession_number":"0001193125-26-167070","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Wave Life Sciences sets Singapore High Court hearing for redomiciliation on Apr 29","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Application to convene shareholder meeting for scheme of arrangement filed Apr 16, 2026; hearing on Apr 29 at 10:00 am SGT.","Deadlines: affidavits due Apr 22 by 4 pm SGT; written submissions due Apr 24 by 4 pm SGT.","Redomiciliation moves parent company from Singapore to Delaware; subject to shareholder and court approval.","Copy of application materials available on investor relations website under Corporate Governance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94226,"accession_number":"0001193125-26-157003","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Wave Life Sciences announces redomiciliation to Delaware, shares to exchange 1:1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Parent company to change from Singapore to Delaware corporation via scheme of arrangement.","All ordinary shares exchanged 1:1 for common stock of new Delaware parent, continues trading as WVE.","Redomiciliation subject to shareholder and Singapore High Court approval; expected mid-2026.","Preliminary proxy filed April 15, 2026; expected tax-free to U.S. shareholders.","Cites administrative efficiencies and reduced compliance costs as benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106439,"accession_number":"0001193125-26-125092","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Wave Life Sciences Announces Positive Interim Phase 1 Data for WVE-007 in Obesity Trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single 240 mg dose of WVE-007 reduced visceral fat by 14% (placebo-adjusted, p<0.05) at six months.","WVE-007 showed preservation of lean mass (+2%) and waist circumference reduction (-3%) at six months.","Phase 2a portion of INLIGHT in higher BMI (35-50 kg/m2) to initiate in 2Q 2026.","WVE-007 continues to be generally safe and well tolerated with no severe TEAEs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106438,"accession_number":"0001193125-26-073437","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Wave Life Sciences Q4 net loss $53.2M; cash $602.1M; WVE-007 obesity data update expected Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $53.2M in Q4 vs income $29.3M YoY; full year loss $204.4M vs $97.0M.","Cash $602.1M as of Dec 31, 2025, up from $302.1M; runway into 3Q 2028.","WVE-007 obesity: INLIGHT Phase 1 showed fat loss similar to GLP-1 at 240mg; Phase 2a multidose planned 1H 2026.","WVE-006 for AATD: regulatory engagement for accelerated approval; feedback expected mid-2026; 400mg multidose data in Q1 2026.","GSK collaboration selected fourth program in Jan 2026; eligible for up to $2.8B milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":42727000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106437,"accession_number":"0001193125-26-032698","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Wave regains full rights to WVE-006; plans FDA accelerated approval engagement mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Regained full rights to WVE-006 (RNA editing for AATD) from GSK; no upfront payment mentioned.","Plans to engage FDA on accelerated approval pathway; regulatory feedback expected mid-2026.","400 mg multidose cohort data from RestorAATion-2 on track for Q1 2026; 600 mg data expected in 2026.","GSK collaboration continues; fourth program selected in Jan 2026; potential milestones up to $2.8B.","Cash runway expected into Q3 2028; milestone payments from GSK not included in runway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106436,"accession_number":"0001193125-26-009784","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Wave Life Sciences reports preliminary $602M cash; outlines 2026 pipeline milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash $602M as of Dec 31, 2025; runway into 3Q 2028.","WVE-007 Phase 2a multidose for obesity to start 1H 2026; 400mg 3-mo & 240mg 6-mo data due Q1 2026.","WVE-006 400mg multidose data from RestorAATion-2 expected Q1 2026; CTA for WVE-008 in 2026.","NDA filing for WVE-N531 (DMD exon 53 skipping) on track for 2026.","Plan to submit IND for WVE-003 (Huntington's) with prospective strategic partner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122786,"accession_number":"0001193125-25-314746","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Wave Life Sciences prices upsized $402.5M public offering; extends cash runway to Q3 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering: 15,789,475 shares at $19.00 plus 2,631,578 pre-funded warrants at $18.9999.","Underwriters fully exercised option for additional 2,763,157 shares; total gross proceeds ~$402.5M.","Closing expected Dec 11, 2025; pro forma shares outstanding ~187.7M.","Cash runway extended into Q3 2028; excludes potential milestone payments from GSK collaboration.","Jefferies, Leerink Partners, BofA Securities act as joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122785,"accession_number":"0001193125-25-310595","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Wave Life Sciences reports positive Phase 1 INLIGHT data: WVE-007 reduces visceral fat 9.4%, preserves lean mass","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single 240 mg WVE-007 dose: 9.4% visceral fat loss (p=0.02), 4.5% total fat reduction, 3.2% lean mass gain at 3 months.","Serum Activin E suppressed up to 78%; durable reductions support once or twice-yearly dosing.","No severe TEAEs, no discontinuations, no clinically meaningful changes in lipids or liver function.","Phase 2 planning for monotherapy, add-on to incretins, and maintenance post-incretin therapy.","Next data: Q1 2026 6-month follow-up from 240 mg cohort and 3-month from 400 mg cohort."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122784,"accession_number":"0001193125-25-283929","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Wave Life Sciences updates corporate presentation; no material new data disclosed.","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed corporate presentation dated November 17, 2025, available on company website.","Presentation includes business update summary; no specific financial figures or milestones provided in the filing.","No changes to prior guidance or pipeline status reported in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122783,"accession_number":"0001193125-25-273278","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Wave Life Sciences Q3 net loss $53.9M; obesity drug WVE-007 shows 85% Activin E reduction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["WVE-007: dose-dependent Activin E reduction up to 85% in INLIGHT; sustained through 6 months at lowest dose; supports once/twice yearly dosing.","WVE-006 recapitulated MZ phenotype: AAT >20 µM during acute phase, wild-type M-AAT 64% of serum AAT, Z-AAT reduced 60% in RestorAATion-2.","Cash $196.2M at Sept 30; $72.1M post-quarter from ATM and GSK milestones extend runway into Q2 2027.","Net loss $53.9M vs $61.8M prior year; revenue $7.6M vs ($7.7M); R&D $45.9M, G&A $18.1M.","Milestones: INLIGHT body weight data Q4 2025; NDA for WVE-N531 in 2026; IND for WVE-003 Phase 2/3 H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122781,"accession_number":"0001193125-25-257298","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K/A","filed_at":"2025-10-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Wave Life Sciences reports positive WVE-007 target engagement: up to 85% Activin E reduction; WVE-008 candidate selected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["WVE-007 Activin E reductions: 85% (400mg), 75% (240mg), 56% (75mg) at day 29; Cohort 1 durable through 6 months, supporting 1-2x/year dosing.","WVE-007 safe/well-tolerated; DMC cleared dose expansion to 600mg and beyond. Body composition/weight data updates expected starting 4Q2025.","WVE-008 selected as PNPLA3-I148M RNA editing candidate for liver disease; CTA filing expected in 2026. Estimated 9M homozygous patients in US/EU.","WVE-006 AATD cohort 3 (600mg) now underway; previously restored 13 µM total AAT with 64% M-AAT. Multidose data expected 1Q2026.","Platform data: single oligonucleotide can simultaneously edit and silence two targets (LDLR up, PCSK9 down) in preclinical models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122782,"accession_number":"0001193125-25-256682","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Wave Life Sciences reports positive target engagement data for WVE-007 in obesity; Activin E reductions up to 85%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["WVE-007 achieved Activin E reductions of 85% (400mg), 75% (240mg), 56% (75mg) at one month, all highly significant (p<0.0001).","75mg cohort showed durable reduction through 6 months, supporting once or twice yearly dosing.","WVE-007 safe and well tolerated; independent data monitoring committee supported dose expansion and escalation.","Multiple clinical data updates including body composition and weight expected starting 4Q2025.","Announced WVE-008 RNA editing candidate for PNPLA3 liver disease; CTA filing anticipated in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139474,"accession_number":"0001193125-25-214176","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2025-09-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Wave Life Sciences releases updated corporate presentation on September 24, 2025","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted on company website and furnished as Exhibit 99.1.","Exhibit text only includes title page; no detailed slides or new data in filing.","Investors should refer to the full presentation on the company's IR website.","No specific financial or pipeline updates are disclosed in this 8-K exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139473,"accession_number":"0001193125-25-194511","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Wave Life Sciences reports positive WVE-006 data in alpha-1 antitrypsin deficiency study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["200 mg repeat doses achieved 11.9 µM total AAT and 7.2 µM M-AAT, meeting therapeutic levels","Individual during acute phase response showed 20.6 µM total AAT and 10.3 µM M-AAT, first demonstration of restored physiological production","Single 400 mg dose achieved 12.8 µM total AAT and 5.3 µM M-AAT; monthly dosing supported","GSK holds exclusive global license for WVE-006; Wave eligible for up to $525M milestones plus royalties","Data support monthly or less frequent subcutaneous dosing; 400 mg multidose cohort data expected Q1 2026"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139472,"accession_number":"0001193125-25-178083","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Wave Life Sciences shareholders approve 8M share increase to equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved 8M share increase to 2021 Equity Incentive Plan (105.9M for, 24.6M against).","All nine director nominees re-elected, including Paul Bolno and Christian Henry.","KPMG ratified as independent auditor for FY2025 with 144.5M votes for.","Advisory executive compensation vote passed with 129.6M for; shareholders favored annual frequency (130.2M for one-year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139471,"accession_number":"0001193125-25-173053","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Wave Life Sciences updates corporate presentation on August 5, 2025","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Company furnished an updated corporate presentation as Exhibit 99.1 to the 8-K.","Presentation is available on the 'For Investors & Media' section of Wave Life Sciences' website.","Information provided under Item 7.01 Regulation FD is furnished, not filed.","Presentation contains business updates and summaries for the investment community."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139470,"accession_number":"0001193125-25-168644","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Wave Life Sciences Q2 2025 net loss $50.5M; cash $208.5M; key trial data on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $208.5M as of June 30, 2025, down from $302.1M at Dec 31, 2024; runway into 2027.","Revenue $8.7M in Q2 2025 vs $19.7M YoY; net loss $50.5M vs $32.9M YoY.","WVE-006 AATD: multidose complete in 200mg cohort; 200mg data in 3Q 2025, 400mg data fall 2025.","WVE-007 obesity: expanded Cohort 2 (240mg) to 32; data from Cohorts 1 and 2 expected 4Q 2025.","Appointed Christopher Wright, MD, PhD, as Chief Medical Officer in May 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":17874000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157056,"accession_number":"0001193125-25-115489","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Wave Life Sciences Q1 2025 net loss $46.9M; pipeline progress in obesity, AATD, DMD, HD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $46.9M vs $31.6M prior year; revenue $9.2M (down from $12.5M). Cash $243.1M, runway into 2027.","Obesity: dosing complete in first two INLIGHT cohorts for WVE-007; clinical data expected 2H 2025.","AATD: RestorAATion-2 dosing at 200 mg Q2W and 400 mg single dose; data on multiple cohorts due 3Q and fall 2025.","DMD: Positive 48-week FORWARD-53 data with 3.8 sec improvement in TTR vs natural history; NDA submission planned 2026.","HD: IND submission expected 2H 2025 for potentially registrational Phase 2/3 study of WVE-003."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":9175000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175410,"accession_number":"0001193125-25-063184","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Wave reports positive Phase 2 FORWARD-53 data for WVE-N531 in DMD; plans NDA in 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TTR improved 3.8 seconds vs natural history (p<0.05); fibrosis reduced 28.6% (p<0.01); CK declined 50%.","Mean dystrophin 7.8% (88% >5%); muscle health reversal shown; no SAEs.","FDA confirms accelerated approval pathway; NDA filing planned in 2026 based on all FORWARD-53 data.","Monthly dosing supported by 61-day half-life; additional DMD exons (52,51,45,44) CTAs expected in 2026 addressing ~$2.4B US market.","Pipeline milestones: WVE-006 AATD data, WVE-007 obesity data H2 2025, WVE-003 HD IND H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175409,"accession_number":"0001193125-25-044876","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Wave Life Sciences Q4 net income $29.3M; cash $302M; obesity and AATD data expected in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $83.7M (up from $29.1M YoY); net income $29.3M vs prior year net loss $16.3M.","Full year 2024 net loss $97.0M, compared to $57.5M in 2023; R&D expenses increased to $159.7M.","Cash $302.1M as of Dec 31, 2024, expected operating runway into 2027; excludes potential GSK milestones.","Dosing underway in INLIGHT trial of WVE-007 in obesity; clinical data expected 2H 2025.","On track to deliver FORWARD-53 48-week DMD data and FDA feedback on accelerated approval in 1Q 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175408,"accession_number":"0001193125-25-005233","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Wave Life Sciences updates corporate presentation, no material details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished an updated corporate presentation on January 13, 2025.","Presentation is available on the company's investor relations website.","No specific financial data, pipeline updates, or milestones were provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192362,"accession_number":"0001193125-24-262067","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Wave Life Sciences updates corporate presentation; no specific new data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company filed an updated corporate presentation dated November 20, 2024.","Presentation is available on the company's investor website.","No financial results, guidance, or pipeline updates are included in the filing.","Filing is a routine disclosure with no material new information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192361,"accession_number":"0001193125-24-255157","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Wave Life Sciences Q3 net loss $61.8M; first RNA editing in humans for AATD achieved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $61.8M vs net income $7.3M in Q3 2023; revenue ($7.7M) vs $49.2M (including one-time events).","Cash $310.9M at Sep 30, 2024; plus ~$28M net proceeds from greenshoe; runway into 2027.","First-ever RNA editing in humans: WVE-006 in RestorAATion-2 showed mean M-AAT 6.9 µM at day 15 (60%+ of total AAT).","WVE-007 (INHBE GalNAc-siRNA) obesity clinical trial on track for 1Q 2025; preclinical data supports monotherapy and GLP-1 synergy.","WVE-003 HD: FDA open to caudate atrophy endpoint for accelerated approval; IND submission expected 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192360,"accession_number":"0001193125-24-247660","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Wave Life Sciences reveals WVE-007 obesity trial startup in Q1 2025, new RNA editing programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["WVE-007 (INHBE GalNAc-siRNA) on track for Phase 1 in Q1 2025; preclinical data show monotherapy, add-on to GLP-1s, and maintenance potential.","Three new wholly owned GalNAc-RNA editing programs: PNPLA3, LDLR, APOB targeting cardiometabolic diseases; candidate selection expected in 2025.","Wave aims to have five GalNAc-siRNA or RNA editing programs in the clinic by 2026.","Proprietary chemistry innovations (PN backbone, N3U) enhance intracellular delivery and RNA editing efficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192359,"accession_number":"0001193125-24-237869","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Wave achieves first-ever therapeutic RNA editing in humans in RestorAATion-2 trial of WVE-006","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single 200 mg dose in first two Pi*ZZ patients produced mean total AAT ~11 µM at day 15, with edited M-AAT >60% of total.","Wild-type M-AAT reached mean 6.9 µM at day 15, consistent with MZ genotype with low AATD risk.","WVE-006 well-tolerated; all adverse events mild/moderate, no SAEs; multidose data expected 2025.","Wave eligible for up to $525M milestones + royalties from GSK; Research Day Oct 30 to show pipeline.","AATD affects ~200,000 in US/EU; current therapy limited to weekly IV augmentation (>$1.4B sales); no approved liver disease therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192358,"accession_number":"0001193125-24-237665","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Takeda terminates HTT option; Wave Life Sciences regains full rights to WVE-003 Huntington's program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Takeda notified Wave it will not exercise option for HTT target, ending collaboration; Takeda previously paid ~$260M to Wave.","Wave regains full rights to WVE-003 and all HTT-targeting programs, with potential $5B-$10B commercial opportunity.","SELECT-HD clinical trial data generated significant interest from prospective partners for WVE-003.","Wave expects regulatory feedback on accelerated approval pathway for WVE-003 by end of 2024.","Cash runway unchanged into 2027, excluding potential GSK milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192357,"accession_number":"0001193125-24-229513","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Wave Life Sciences posts updated corporate presentation to IR website","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation dated October 1, 2024, posted on investor relations page.","No specific details (financials, pipeline updates, milestones) disclosed in the filing text.","Presentation is standard periodic update for the investment community.","No guidance, material events, or changes to business outlook mentioned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208829,"accession_number":"0001193125-24-227053","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Wave Life Sciences prices upsized $200M public offering of ordinary shares and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 23.1M ordinary shares at $8.00/share and 1.9M pre-funded warrants at $7.9999 each; gross proceeds ~$200M.","Underwriters have 30-day option to purchase up to an additional 3.75M ordinary shares on same terms.","Offering expected to close on or about Sept 27, 2024; cash runway extended into 2027 excluding GSK/Takeda milestones.","Following close, pro forma ordinary shares outstanding expected to be approximately 148.4M.","J.P. Morgan and Leerink Partners acting as joint book-running managers; Truist and Mizuho as book-runners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208828,"accession_number":"0001193125-24-224116","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2024-09-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Wave Life Sciences reports positive interim Phase 2 data for WVE-N531: adjusted dystrophin 9.0% in DMD exon 53","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean muscle content-adjusted dystrophin expression 9.0% (range 4.6-13.9%); unadjusted 5.5% (range 3.3-8.3%) in ambulatory boys.","Dystrophin isoforms consistent with milder Becker DMD; 89% of ambulatory participants achieved ≥5% adjusted dystrophin.","WVE-N531 safe and well tolerated; all treatment-related AEs mild, no serious AEs or discontinuations.","Muscle concentration ~41,000 ng/g; 61-day half-life supports monthly dosing; preclinical data suggest higher concentration in heart/diaphragm.","Wave expects regulatory feedback and complete 48-week FORWARD-53 data in 1Q 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208827,"accession_number":"0001193125-24-199020","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve increase to equity plan shares by 5M at Wave Life Sciences AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2021 Equity Incentive Plan, increasing share authorization by 5,000,000 shares.","Proposal passed with 82,321,912 for, 12,184,069 against, 32,017 abstain.","Nine directors re-elected; Christian Henry received 80,627,620 for, 13,894,737 against.","KPMG LLP re-appointed as auditor with 101,761,729 for, 316,576 against.","Say-on-pay advisory vote passed with 94,163,361 for, 356,573 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208826,"accession_number":"0001193125-24-196489","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Wave Life Sciences Q2 net loss $32.9M; positive HD data with up to 46% mHTT reduction; cash $154M into Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $32.9M vs $21.1M YoY; revenue $19.7M vs $22.1M; cash $154M, sufficient into Q4 2025.","SELECT-HD: WVE-003 reduced mutant HTT up to 46%, statistically significant; slowing caudate atrophy; Takeda opt-in submitted.","DMD: FORWARD-53 dystrophin data expected 3Q2024; WVE-N531 previously showed 53% exon skipping.","AATD: RestorAATion-2 dosing initiated; proof-of-mechanism data expected 4Q2024.","Obesity: WVE-007 FIH study expected Q1 2025; preclinical data at R&D Day Fall 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":32230000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226616,"accession_number":"0001193125-24-167481","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Wave Life Sciences reports 46% mHTT lowering in HD trial; allele-selective silencing demonstrated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SELECT-HD: 30 mg WVE-003 Q8W showed 46% mean mHTT reduction vs placebo at 24 weeks (p=0.0007); 44% at 28 weeks (p=0.0002).","Wild-type HTT preserved; allele-selective silencing confirmed.","mHTT reduction correlated with slowing of caudate atrophy (R=-0.50, p=0.047), an imaging biomarker predictive of clinical outcomes.","Generally safe and well-tolerated; no serious adverse events reported.","Cash runway into Q4 2025; Wave to discuss accelerated approval path with regulators."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226615,"accession_number":"0001193125-24-134769","cik":1631574,"company_name":"Wave Life Sciences Ltd.","ticker":"WVE","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Wave Life Sciences Q1 net loss $31.6M; cash $180.9M; pipeline milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $12.5M (vs $12.9M YoY); net loss $31.6M (vs $27.4M). Cash $180.9M; plus $12M from GSK milestone in April.","RestorAATion-2 for AATD underway; proof-of-mechanism data expected in 2024.","INHBE obesity program targets 1Q 2025 trial start; preclinical weight loss similar to semaglutide with fat loss, no muscle loss.","FORWARD-53 DMD 24-week dystrophin data expected 3Q 2024; SELECT-HD multi-dose data expected 2Q 2024.","Appointed Dr. Erik Ingelsson as CSO to drive genetic target discovery; GSK advanced two programs triggering $12M payment."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":12538000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1181350000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}